Discovery of Key Proteins Associated with Rare Autoimmune Vasculopathy
Researchers have identified two proteins, CCN1 and CCN2, that play a crucial role in blood vessel thickening in autoimmune vasculopathy, a complication of antiphospholipid syndrome, opening new avenues for targeted treatments.
Recent research has shed light on the molecular mechanisms underlying antiphospholipid syndrome (APS), a rare autoimmune disorder affecting approximately 1 in 2,000 individuals. APS is primarily known for increasing the risk of blood clots, such as deep vein thrombosis and strokes. However, an often underestimated complication is APS vasculopathy, which impacts 10-20% of patients by causing abnormal thickening of blood vessel walls, leading to narrowing of the vessel lumen. This process compromises blood flow, especially in small vessels supplying vital organs like the kidneys, heart, and skin, potentially resulting in organ damage and failure.
A groundbreaking study led by Dr. Jason Knight at the University of Michigan utilized skin biopsies from patients with severe APS to investigate the disease at a cellular level using single-cell sequencing. The researchers identified two proteins, CCN1 and CCN2, that were significantly overexpressed in blood vessel cells of APS patients. These proteins are known for their roles in tissue scarring (fibrosis), but in this context, they appear to promote the proliferation of endothelial and smooth muscle cells within blood vessel walls. This proliferation thickens the vessel walls and reduces blood flow.
Among the two proteins, CCN2 demonstrated a particularly strong influence on vascular cell behavior, suggesting it as a promising target for future therapies. Although biologic drugs targeting CCN2 are already available, researchers emphasize the need for further clinical trials specifically for APS treatment. Additionally, the study revealed that overexpression of CCN1 and CCN2 is also evident in kidney tissues of APS patients, indicating that skin biopsies might serve as accessible indicators of deeper organ involvement.
The findings pave the way for developing innovative treatments aimed at preventing organ deterioration caused by APS vasculopathy. Dr. Shi highlighted the importance of ongoing efforts to monitor patient cohorts over time, which will help understand disease progression and facilitate the design of effective clinical trials. This research marks a significant step toward targeted therapies that could mitigate the severe complications associated with APS.
Source: https://medicalxpress.com/news/2025-09-key-proteins-rare-autoimmune-disease.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Insulin Production in the Brain: A Surprising Fact Challenging Traditional Views
New research reveals that the brain produces insulin itself, challenging the traditional view that insulin is only made in the pancreas and opening new avenues for understanding brain health and disease.
New Research Uncovers How Tirzepatide and Semaglutide Differ in Their Metabolic Effects
Animal studies reveal that tirzepatide temporarily increases energy expenditure, while semaglutide initially decreases it, offering new insights into obesity treatment mechanisms.
FDA Ends Sales of Off-Brand GLP-1 Medications Like Ozempic
The FDA has halted the sale of off-brand GLP-1 medications like Ozempic, raising safety and access concerns for patients relying on compounded drugs for weight loss and diabetes management.